Corporate news
Grifols Expands its Blood Typing Solutions Portfolio in the United States with Antisera Reagents Grifols conventional antisera reagents recently received licensing approval by the U.S. Food & Drug Administration for manual testing in immunohematology laboratories
+ info
+ info
Grifols reaches an agreement with Boya Bio-Pharmaceutical to open plasma collection centers in China Grifols reinforces its long-term strategy to expand and diversify its access to plasma
+ info
+ info
Grifols increases its net profit by 7% to Euros 143 million and delivers significant growth in organic sales First Quarter 2018 Results
+ info
+ info
Highlights
Manufacturing
We are a solid company with an international dimension.
Corporate Commitment
We contribute to improving people's health and wellbeing by offering safe, high quality products produced using the latest environmentally friendly technology.
When a Dream Comes True. An Illustrated History of 75 Years of Grifols
Read When a Dream Comes True: An illustrated history of 75 years of Grifols to discover the company's roots, and learn more about our history and the development of the company. + info